Collagen continues to dominate the functional ingredient market across foods, beverages, supplements, and beauty-from-within products. From protein powders and ready-to-drink beverages to gummies and nutrition bars, collagen ingredients are now widely incorporated into consumer products targeting skin health, joint support, healthy aging, and sports nutrition.
As innovation in the collagen space expands, manufacturers are increasingly asking an important regulatory question:
Is collagen considered GRAS in the United States?
The short answer is yes — many collagen ingredients may be marketed based on GRAS conclusions in the United States. However, GRAS status is ingredient-specific and depends heavily on the source material, manufacturing process, composition, intended use, and available scientific evidence.
Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), substances intentionally added to food are considered food additives unless they are exempt from premarket approval requirements.
One of the primary exemptions is GRAS — Generally Recognized as Safe. A substance may be considered GRAS when qualified experts generally recognize it as safe under the intended conditions of use.
For collagen ingredients, GRAS status is not automatically granted simply because collagen itself is widely consumed. The regulatory assessment applies to the specific collagen ingredient and its intended application.
Many collagen ingredients benefit from a strong history of consumption because collagen is naturally present in animal-derived foods and has long been used in food and supplement applications.
Common collagen sources include:
Hydrolyzed collagen peptides are also widely used across conventional foods and dietary supplements.
However, regulatory status still depends on several factors, including:
At dicentra, we often see companies assume that all collagen ingredients are treated identically from a regulatory perspective. In reality, novel manufacturing methods, fermentation-derived collagen analogs, concentrated peptide fractions, or highly functionalized collagen ingredients may require additional scientific substantiation.
Collagen ingredients have successfully entered the U.S. market through GRAS pathways supported by scientific safety evaluations.
Several collagen and collagen-related ingredients have already received an FDA “no questions” letter, indicating the agency has no further questions regarding the notifier’s GRAS conclusion when supported by appropriate scientific evidence.
For example:
These examples demonstrate how collagen-related GRAS evaluations can apply to a broad range of ingredient types, manufacturing technologies, and intended food uses. They also reinforce an important regulatory principle: GRAS conclusions are ingredient-specific and depend on manufacturing methods, specifications, intended use levels, and supporting scientific evidence.
In the case of GRN 001171, FDA ultimately responded that it had “no questions” regarding the notifier’s conclusion that the ingredient was GRAS under its intended conditions of use.
Beyond FDA-notified GRAS conclusions, many collagen ingredients are also marketed under self-affirmed GRAS determinations supported by independent expert panel reviews and safety assessments.
Collagen peptides continue to receive significant scientific attention due to their broad use in food, beverage, and nutraceutical applications.
Published literature has discussed:
In addition to these considerations, source-specific safety controls are commonly evaluated during safety assessments. For bovine-derived collagen, this may include controls related to bovine spongiform encephalopathy/transmissible spongiform encephalopathy (BSE/TSE) risk mitigation and raw material traceability. For marine-derived collagen, contaminant monitoring such as heavy metals and environmental pollutants is typically considered as part of quality and safety evaluations.
Published reviews and safety assessments have generally described collagen peptides as having a strong history of use in foods and dietary supplements, while also noting the importance of ingredient characterization, manufacturing quality, contaminant controls, and appropriate intake levels. This is particularly important as the collagen market expands into:
Many collagen ingredients first enter the market through dietary supplements. However, regulatory considerations can change significantly when collagen is added to conventional foods and beverages.
For food applications, manufacturers may need to evaluate:
This distinction becomes especially important for novel collagen technologies, including:
At dicentra, we frequently help companies determine whether an ingredient’s intended commercialization strategy aligns appropriately with its regulatory positioning.
A GRAS evaluation for collagen ingredients often includes:
FDA also expects GRAS conclusions to be supported by publicly available scientific evidence and general recognition among qualified experts.
Depending on the ingredient and intended application, additional studies or supporting documentation may also be necessary.
The collagen market is no longer limited to traditional bovine or marine collagen powders.
Today, companies are developing:
As innovation expands, regulatory strategy becomes increasingly important — particularly when ingredients move into conventional foods and beverages or involve novel production technologies.
dicentra supports companies who are developing collagen ingredients, peptide ingredients, and functional food technologies to enter the U.S. market.
Our services include:
Whether your company is developing a traditional collagen peptide, a fermentation-derived collagen ingredient, or a next-generation collagen technology, our team can help evaluate the appropriate regulatory pathway and support commercialization planning.
If your company is evaluating collagen ingredients for use in foods, beverages, or supplements in the United States, reach out to dicentra to discuss your GRAS strategy, regulatory considerations, and market entry pathway.
Talk to our team about your go to market strategy for collagen →